Nkọwa
Ndị etiti anyị tofacitinib dị oke egwu na usoro mmepụta nke tofacitinib, ọgwụ a ma ama nke a na-eji agwọ ụfọdụ ụdị ọrịa ogbu na nkwonkwo.Nke a dị n'etiti na-arụ ọrụ dị mkpa na mmepụta nke tofacitinib, na-enye aka na ịdị irè ya na ịdị mma ya.Site (2R, 3R) -2,3-bis [(4-methylbenzoyl) oxy] succinic acid na (3R,4R) -N,4-dimethyl-1- (phenylmethyl) - Ngwakọta ziri ezi nke 3-piperidinamines, anyị. ngwaahịa na-eme ka njikọ nke tofacitinib dị elu nke na-ezute ma gafere ụkpụrụ ụlọ ọrụ.
Usoro ihe omimi na ịdị arọ nke etiti tofacitinib anyị na-egosipụta ịdị ọcha na ike ya, na-eme ka ọ bụrụ ihe a pụrụ ịdabere na ya nke usoro mmepụta ọgwụ.Site na ihe eji eme ya nke ọma, etiti a na-ekwe nkwa ngbanwe na ịdị irè nke ngwaahịa ikpeazụ, tofacitinib.Njirimara molekụla ya na-enyekwa aka na nkwụsi ike zuru oke na ndụ nchekwa nke tofacitinib, na-ahụ na ọ na-anọgide na-arụ ọrụ na ntụkwasị obi ruo ogologo oge.
Họrọ Anyị
JDK nwere ụlọ nrụpụta klaasị mbụ yana akụrụngwa njikwa ogo, nke na-emesi nnabata nke etiti API kwụsiri ike.Ndị otu ọkachamara na-emesi R&D obi ike maka ngwaahịa a.megide abụọ, anyị na-achọ CMO & CDMO n'ime ụlọ na mba ahịa.